Back to Search Start Over

Squamous cell lung cancer: genomic evolution and personalized therapy

Authors :
Andrés F Cardona
Luisa Ricaurte
Zyanya Lucia Zatarain-Barrón
Oscar Arrieta
Source :
Salud Pública de México, Vol 61, Iss 3, may-jun, Pp 329-338 (2019)
Publication Year :
2019
Publisher :
Instituto Nacional de Salud Pública, 2019.

Abstract

Objective. To review the state-of-the-art in relation to the current information on squamous cell lung cancer (SCLC). We describe the genetic anomalies reported, their effect, and fi­nally the most promising therapeutic agents. Materials and methods. We reviewed published articles in peer-reviewed journals as well as current treatment guidelines from local and international resources. Results. SCLC represents a smaller proportion of the global burden of disease for lung cancer compared to its more frequent presentation, the ade­nocarcinoma. However, more than 400 000 cases are reported annually, a substantial population for whom therapeutic op­tions are scarce and with limited efficacy. Several groups have been given the task of elucidating the mechanisms that lead to the development of SCLC, including molecular anomalies that can be used as targets for drug design. Conclusion. There are potential therapeutic targets for SCLC, which must be studied in clinical trials for validation.

Details

Language :
English, Spanish; Castilian
ISSN :
00363634
Volume :
61
Issue :
3, may-jun
Database :
Directory of Open Access Journals
Journal :
Salud Pública de México
Publication Type :
Academic Journal
Accession number :
edsdoj.9f3215d859741b0afc4958aef058fc9
Document Type :
article
Full Text :
https://doi.org/10.21149/10115